28,722 Shares in Pfizer Inc. $PFE Bought by SummitTX Capital L.P.

Posted by Geri Gentry on Jul 31st, 2026

SummitTX Capital L.P. acquired a new position in shares of Pfizer Inc. (NYSE:PFE – Free Report) in the 1st quarter, Holdings Channel.com reports. The fund acquired 28,722 shares of the biopharmaceutical company’s stock, valued at approximately $807,000.

Other hedge funds have also bought and sold shares of the company. Norges Bank bought a new stake in shares of Pfizer in the 4th quarter worth about $1,830,986,000. Morgan Stanley raised its position in Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Bank of New York Mellon Corp lifted its stake in Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Pfizer by 577.5% during the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after buying an additional 7,489,189 shares during the period. Finally, Capital World Investors boosted its position in shares of Pfizer by 51.5% during the fourth quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock valued at $533,704,000 after buying an additional 7,287,194 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.9%

PFE opened at $24.92 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock’s fifty day moving average is $25.06 and its two-hundred day moving average is $26.16. The company has a market capitalization of $142.04 billion, a P/E ratio of 19.02 and a beta of 0.35. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the prior year, the business earned $0.92 EPS. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is 131.30%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. JPMorgan Chase & Co. cut their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. BMO Capital Markets reduced their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.50.

Get Our Latest Stock Report on Pfizer

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Encouraging vitiligo data could strengthen Pfizer’s growth pipeline. Two Phase 3 trials showed that LITFULO significantly improved skin repigmentation in patients with nonsegmental vitiligo. Pfizer plans global regulatory submissions, potentially expanding the drug beyond its existing uses and creating a new commercial opportunity. Pfizer’s oral drug restores skin pigmentation in late-stage vitiligo trials
Positive Sentiment: EU authorization for the updated COVID-19 vaccine supports the 2026–2027 season. The European Commission approved Pfizer and BioNTech’s XFG-adapted Comirnaty vaccine for people six months and older across the European Union. The decision allows manufacturing and supply preparations, although the mature and seasonal COVID market may limit the financial upside. Pfizer Wins EU Approval For Updated COVID Vaccine Ahead Of 2026 Season
Positive Sentiment: Pfizer continues to build its oncology pipeline. The company is advancing the Phase 2 Symbiotic-Lung-10 trial, offering potential long-term upside if the lung-cancer program produces favorable results. However, Phase 2 development means any revenue contribution remains several years away. Pfizer’s Symbiotic-Lung-10 Trial
Neutral Sentiment: Investors are focused on the upcoming second-quarter report. Preview reports highlight expectations for key products, COVID-related headwinds, and possible updates to full-year guidance. Pfizer’s latest quarter exceeded estimates, but earnings declined year over year, leaving results and management commentary as the near-term catalysts. Pfizer Q2 Earnings Preview
Positive Sentiment: Additional vaccine demand may support established products. Québec selected Pfizer’s Prevnar 20 for its publicly funded pediatric pneumococcal immunization program, providing a potential boost to vaccine sales and market presence. Pfizer’s PREVNAR 20 Selected for Québec Program

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.